KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Cash (2016 - 2025)

Historic Change in Cash for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $650.4 million.

  • Gsk's Change in Cash rose 95568.41% to $650.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$311.5 million, marking a year-over-year decrease of 18691.28%. This contributed to the annual value of -$233.4 million for FY2025, which is 13048.45% down from last year.
  • As of Q4 2025, Gsk's Change in Cash stood at $650.4 million, which was up 95568.41% from -$841.8 million recorded in Q3 2025.
  • Gsk's 5-year Change in Cash high stood at $9.3 billion for Q1 2022, and its period low was -$8.9 billion during Q4 2022.
  • Over the past 5 years, Gsk's median Change in Cash value was -$449.6 million (recorded in 2024), while the average stood at -$762.1 million.
  • As far as peak fluctuations go, Gsk's Change in Cash tumbled by 2326151.6% in 2022, and later soared by 95568.41% in 2025.
  • Over the past 5 years, Gsk's Change in Cash (Quarter) stood at -$2.7 billion in 2021, then plummeted by 225.47% to -$8.9 billion in 2022, then surged by 93.48% to -$580.9 million in 2023, then skyrocketed by 110.61% to $61.6 million in 2024, then soared by 955.68% to $650.4 million in 2025.
  • Its Change in Cash was $650.4 million in Q4 2025, compared to -$841.8 million in Q3 2025 and -$1.2 billion in Q2 2025.